Prevention by chitosan of myelotoxicity, gastrointestinal toxicity and immunocompetent organic toxicity induced by 5-fluorouracil without loss of antitumor activity in mice

Japanese Journal of Cancer Research

Volumn 90, Issue 7, 1999, Pages 765-774

  Kimura, Yoshiyuki ^a   Okuda, Hiromichi ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Antitumor activity; Chitosan; Prevention of side effects

Indexed keywords

CD8 ANTIGEN; CHITOSAN; FLUOROURACIL; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DIARRHEA; GASTROINTESTINAL TOXICITY; IMMUNOCOMPETENCE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SARCOMA; SMALL INTESTINE; SPLEEN WEIGHT; T LYMPHOCYTE;

EID: 0032800152     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00813.x     Document Type: Article

References (47)

1. Zhou, A., Matsuura, Y. and Okuda, H. Chitosan augments cytolytic activity of mouse lymphocytes. J. Tradit. Med., 11, 62-64 (1994).
2. Kato, H., Taguchi, T., Okuda, H., Kondo, M. and Takara, M. Antihypertensive effect of chitosan in rats and humans. J. Tradit. Med, 11, 198-205 (1994).
3. Han, L.-K., Kimura, Y. and Okuda, H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int. J. Obes., 23, 174-179 (1998).
4. Duschinsky, R., Pleven, E. and Heidelberg, C. The synthesis of 5-fluoropyrimidines. J. Am. Chem. Soc., 79, 4559-4560 (1957).
5. Heidelberg, C. and Ansfield, F. J. Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res., 23, 1226-1243 (1963).
6. Seifert, P., Baker, H. L. and Reed, M. L. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer, 36, 123-128 (1975).
7. Shah, A., MacDonald, W., Goldie, J., Gudauskas, G. and Brisebois, B. 5-FU infusion in advanced colorectal cancer: comparison of three dose schedules. Cancer Treat. Rep., 69, 739-742 (1985).
8. Caballero, G. A., Ausma, R. K. and Quebbema, E. J. Long-term, ambulatory, continuous infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat. Rep., 69, 13-15 (1985).
9. Houghton, J. A., Houghton, P. J. and Wooten, R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res., 39, 2406-2413 (1979).
10. Schetz, J. D., Wallance, H. J. and Diasio, R. B. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res., 44, 1358-1363 (1984).
11. Kimura, Y., Okuda, H. and Arichi, H. Effects of geniposide isolated from Gardenia jasminoides on metabolic alterations in high sugar diet-fed rats. Chem. Pharm. Bull., 30, 4444-4447 (1982).
12. Kimura, Y., Okuda, H. and Arichi, S. Effects of non-sugar fraction in black sugar on lipid and carbohydrate metabolism; part I. Planta Med., 50, 465-468 (1984).
13. Schneider, W. C. Phosphorus compounds in animal tissues. III. Comparison of methods for the estimation of nucleic acid. J. Biol. Chem., 164, 747-751 (1946).
14. Ikenaka, K., Shirasaka, T., Kitano, S. and Fujii, S. Effects of uracil on metabolism of 5-fluorouracil in vitro. Jpn. J. Cancer Res., 70, 353-359 (1979).
15. Ninomiya, Y., Ryu, M., Matsuura, N., Fujimoto, K., Miwa, M. and Ishitsuka, H. Antitumor activity and the toxicity on the immune system and the intestine of fluorinated pyrimidines, FUra, 5′-DFUR, Tegafur and UFT. Jpn. J. Cancer Chemother., 15, 1747-1754 (1988).
16. Kouchi, Y., Maeda, Y., Morinaga, H. and Ohuchida, A. Immunotoxic effects of a new antineoplastic agent S-1 in mice. Comparison with S-1, UFT and 5-FU. J. Toxicol. Sci., 21, 691-701 (1996).
17. 1 mice. J. Toxicol. Sci., 21, 29-39 (1996).
18. Boistea, V., Jern, I. and Lupasco, V. The characteristics of the pathogenesis and immunomodulator treatment in the postoperative period in pseudophakia patients, Ophthalmologia, 40, 210-213 (1996).
19. Ophir, R. M., Recht, M., Keisari, Y., Rashid, G., Lourie, S., Meshore, A., Ben-Efraim, S., Trainin, N. and Burstem, Y. Thymic humoral factor-γ 2 (THF-γ 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy. Immunopharmacol. Immunotoxicol., 18, 209-236 (1996).
20. Fujii, S., Ikenaka, K., Fukushima, M. and Shirasaka, T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann, 69, 763-772 (1978).
21. Ishitsuka, H., Miwa, M., Takemoto, K., Fukuoka, K., Itoga, A. and Maruyama, H. B. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann, 71, 112-123 (1980).
22. Fujii, S., Fukushima, M., Shimamoto, Y., Ohshimo, H., Imaoka, T. and Shirasaka, T. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn. J. Cancer Res., 80, 173-181 (1989).
23. Shirasaka, T., Fukushima, M., Shimamoto, Y., Kimura, Y., Ohshimo, H., Imaoka, T., Kimura, A., Utsunomiya, T. and Fujii, S. Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn. J. Cancer Chemother., 17, 1051-1058 (1990).
24. Ardalam, B., Luis, R., Jaime, M. and Franceschi, D. Biomodulation of fluorouracil in colorectal cancer. Cancer Invest., 16, 237-251 (1998).
25. Kohne, C. H., Harstrick, A., Hiddemann, W., Schoffski, P., Wilke, H., Bokemeyer, C., Dorken, B. and Schmoll, H. J. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study. Eur. J. Cancer, 33, 1896-1899 (1997).
26. Hartmann, J. T., Kohne, G. H., Schmoll, H. J., Daikeler, T., Kanz, L. and Bokemeyer, C. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study. Oncology, 55, 320-325 (1998).
27. Rustum, Y. M., Cao, S. and Zhang, Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cancer J. Sci. Am., 4, 12-18 (1998).
28. Gamelin, E., Boisdrom-Celle, P. E., Delva, R., Regimbeau, C., Cailleux, P. E., Alleaume, C., Maillet, M. L., Goudier, M. J., Sire, M., Person-Joly, M. C., Maigre, M., Maillart, P., Fety, R., Burtin, P., Lortholary, A., Dumensnil, Y., Picon, L., Geslin, J., Gesta, P., Danquechin-Dorval, E., Larra, F. and Robert, J. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J. Clin. Oncol., 16, 1470-1478 (1998).
29. Scanlon, K. J., Newman, E. M. and Priest, D. G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA, 83, 8923-8925 (1986).
30. Shirasaka, T., Shimamoto, Y., Ohshimo, H., Saito, H. and Fukushima, M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor model in vivo. Cancer Chemother. Pharmacol., 32, 167-172 (1993).
31. DeBraud, F., Munzone, E., Noie, F., De-Pas, T., Biffi, R., Brienza, S. and Aapro, M. S. Synergistic activity of oxalipatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive diseases while on or after 5-fluorouracil. Am. J. Clin. Oncol., 21, 279-283 (1998).
32. Clevas, A. D., Busse, P. M., Norris, C. M., Fried, M., Tishler, R. B., Poulin, M., Fabian, R. L., Fitzgerald, T. J., Dreyfuss, A., Peters, E. S., Adak, S., Costello, R., Barton, J. J. and Ponsner, M. R. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J. Clin. Oncol., 16, 1331-1339 (1998).
33. Barone, C., Corsi, D. C., Pozzo, C., Cassano, A., Fontana, T., Noviello, M. R., Landriscina, M., Colloca, G. and Astone, A. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer, 82, 1460-1467 (1998).
34. Meropol, N. J., Blumenson, L. E. and Creaven, P. J. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am. J. Clin. Oncol., 21, 135-138 (1998).
35. Shirasaka, T., Shimamoto, Y. and Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res., 53, 4004-4009 (1993).
36. Sato, M., Onishi, H., Takahara, J., Machida, Y. and Nagai, T. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol. Pharm. Bull., 19, 1170-1177 (1996).
37. Fujii, S., Shimamoto, Y., Ohshimo, H., Imaoka, T., Motoyama, M., Fukushima, M. and Shirasaka, T. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats. Jpn. J. Cancer Res., 80, 167-172 (1989).
38. Caballero, G. A., Ausman, R. K. and Quebbeman, E. J. Long-term, ambulatory, continuous iv infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat. Rep., 69, 13-15 (1985).
39. Schipper, N. G., Varum, K. M. and Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res., 13, 1686-1692 (1996).
40. Schipper, N. G., Olsson, S., Hoogstraate, J. A., deBoer, A. G., Varum, K. M. and Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res., 14, 923-929 (1997).
41. Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T., Yamamoto, A. and Muranishi, S. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci., 86, 1016-1021 (1997).
42. Miekka, S. I., Jameson, T., Singh, M., Woolverton, C., Lin, H. M., Krajcik, R., MacPhee, M. and Drohan, W. N. Novel delivery systems for coagulation proteins. Haemophilia, 4, 436-442 (1998).
43. Sugimoto, K., Yoshida, M., Yata, T., Higaki, K. and Kimura, T. Evaluation of polyfvinyl alcohol)-gel spheres containing chitosan as dosage form to control gastrointestinal transit time of drugs. Biol. Pharm. Bull., 21, 1202-1206 (1998).
44. Singh, U. V. and Udupa, N. Methotrexate loaded chitosan and chitin microspheres - in vitro characterization and pharmacokinetics in mice bearing Ehrlich ascites carcinoma. J. Microencapsul., 15, 581-594 (1998).
45. Al-Helw, A. A., Al-Angary, A. A., Mahrous, G. M. and Al-Dardari, M. M. Preparation and evaluation of sustained release cross-linked chitosan microspheres containing phenobarbitone. J. Microencapsul., 15, 373-382 (1998).
46. Lim, B. O., Yamada, K., Nonaka, M., Kuramoto, Y., Hung, P. and Sugano, M. Dietary fibers modulate indices of intestinal immune function in rats. J. Nutr., 27, 663-667 (1997).
47. Shibata, Y., Foster, L. A., Metzger, W. J. and Myrvik, Q. N. Alveolar macrophages priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice. Infect. Immun., 65, 1734-1741 (1997).